

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS PO. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

•			•		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/828,217	04/09/2001	Toshio Hirano	205721US0CON	6439	
22850 OBLON, SI	7590 05/29/2003 IVAK. MCCLELLAND	, MAIER & NEUSTADT, P.C.	EXAM	INER	
•	1940 DUKE STREET				
ALEXANDE	RIA, VA 22314		MERTZ, PREMA MARIA		
	-		ART UNIT	PAPER NUMBER	
		•	1646		
			DATE MAILED: 05/29/2003	,	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/828,217

Applicant(s)

Hirano et al.

Examiner

Prema Mertz

Art Unit 1646



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address				
Period 1	for Reply					
THE N	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE MONTH(S) FROM no event, however, may a reply be timely filed after SIX (6) MONTHS from the				
mailing - If the p - If NO p - Failure - Any re	date of this communication. period for reply specified above is less than thirty (30) days, a reply within th	ne statutory minimum of thirty (30) days will be considered timely. and will expire SIX (6) MONTHS from the mailing date of this communication. ne application to become ABANDONED (35 U.S.C. § 133).				
Status						
1) 💢	Responsive to communication(s) filed on Apr 1, 20	03				
2a) 💢	This action is FINAL . 2b) ☐ This act	tion is non-final.				
3) 🗆		nis application is in condition for allowance except for formal matters, prosecution as to the merits is n accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposi	tion of Claims					
4) 🗶	Claim(s) <u>8-10</u>	is/are pending in the application.				
4	la) Of the above, claim(s)	is/are withdrawn from consideration	n.			
5) 🗆	Claim(s)	is/are allowed.				
6) 💢	Claim(s) <u>8-10</u>	is/are rejected.				
7) 🗆	Claim(s)	is/are objected to.				
8) 🗌	Claims	are subject to restriction and/or election requiremen	١t.			
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.				
	Applicant may not request that any objection to the d					
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Exam	iner.			
	If approved, corrected drawings are required in reply t	to this Office action.				
12)	The oath or declaration is objected to by the Exami	iner.				
Priority	under 35 U.S.C. §§ 119 and 120					
13)🗶	Acknowledgement is made of a claim for foreign pro-	riority under 35 U.S.C. § 119(a)-(d) or (f).				
a) 🕽	All b) □ Some* c) □ None of:					
	1. \square Certified copies of the priority documents hav	ve been received.				
	2. X Certified copies of the priority documents hav	ve been received in Application No08/624,650				
	application from the International Bure					
_	ee the attached detailed Office action for a list of the					
14) 📙	Acknowledgement is made of a claim for domestic					
a) ∟						
15) □	Acknowledgement is made of a claim for domestic	priority under 30 O.S.C. 33 TZO driu/OFTZT.				
Attachm	ent(s) otice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)				
	formation Disclosure Statement(s) (PTO-1449) Paper No(s)8	6) Other:				

Application/Control Number: 09/828,217

Art Unit: 1646

DETAILED ACTION

- 1. Claims 1-7 have been canceled previously. Claims 9-10 and amended claim 8 (Paper No. 7, 4/1/03), are under consideration.
- 2. Receipt of applicant's arguments and amendments filed in Paper No. 7 (4/1/03) is acknowledged.
- 3. The following previous rejections and objections are withdrawn in light of applicants amendments filed in Paper No. 7, 4/1/03:
- (i) the rejection of claim 10 under 35 U.S.C. § 112, first paragraph.
- 4. Applicant's arguments filed in Paper No. 4 (4/1/03), have been fully considered but were persuasive in part. The issues remaining and new issues, are stated below.
- 5. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 102

6. Claims 8-9 are rejected under 35 U.S.C. 102(a) as being anticipated by Goto et al. (1992) in light of WO98/35698.

This rejection is maintained for reasons of record set forth at pages 4-5 of the previous Office action (Paper No. 5, 10/1/02).

Applicants argue that the Goto et al reference does not teach about specific amino acid sequences and the pre-B cell growth-supporting ability thereof and therefore fails to describe the claimed antibody. However, contrary to Applicants' arguments, the instant protein of SEQ ID

Application/Control Number: 09/828,217

Art Unit: 1646

NO:1 is indistinguishable from the prior art protein. A copy of the comparison of SEQ ID NO:1 (SEQUENCE COMPARISON 'A') of the protein of the instant invention to which the claimed antibodies are drawn, and the amino acid sequence of the protein in the reference to which the antibody MoAb HM1.24 is drawn, has been enclosed at the end of the last office action (Paper No. 5, 10/1/02). WO98/35698 reference is being relied upon because it teaches the amino acid sequence of HM1.24 protein (see SEQ ID NO:1, pages 44-45), the amino acid sequence being an inherent characteristic of the protein. The combination of the Goto et al and WO98/35698 reference show that the monoclonal antibody HM1.24 disclosed against a specific protein in the Goto et al reference, anticipates the instant claims, because the HM1.24 protein is 100% identical to the instant protein of SEQ ID NO:1 as disclosed by the WO98/35698 reference.

Where the Patent Office has reason to believe that a functional limitation, i.e. pre-B cell growth-supporting ability, asserted to be critical for establishing novelty in the claimed subject matter may be an inherent characteristic of the prior art, it has the authority to require the applicant to prove that the subject matter shown in the prior art does not possess the characteristics relied on. <u>In re Schreiber</u>, 44 USPQ2d 1429 (Fed. Cir. 1997).

Products of identical chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). See MPEP.. 2112.01.

Application/Control Number: 09/828,217

Art Unit: 1646

"From the standpoint of patent law, a compound and all of its properties are inseparable; they are one and the same thing." see <u>In re Papesch</u>, 315 F. 2d 381, 391, 137 USPQ 43, 51 (CCPA 1963).

Therefore, since the protein in the reference appears to be consistent with the protein in the instant application, the claimed antibody to the polypeptide would be the same as the antibody to the polypeptide of the reference. Since the Office does not have the facilities for examining and comparing Applicants' antibody with the antibody of the prior art, the burden is upon the applicants to show the novel difference between the protein of the instant application and that of the Goto et al reference.

Conclusion

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however,

Application/Control Number: 09/828,217 Page 5

Art Unit: 1646

will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (703) 308-4229. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 305-3014 or (703 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 746-5300.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Prema Mertz Ph.D. Primary Examiner Art Unit 1646 May 20, 2003